Grzybowski et al. conducted a study using an OATD-02 inhibitor in combination therapy with a STING agonist (DMXAA) and immune checkpoint inhibitors, thereby improving the anti-tumor response [17,190]. This evidence concerns the gene STING1 and neoplasm.